Dual-State KRAS G12C Inhibitors as Emerging Therapeutics for Brain and Lung Metastases
Anna C Renner1, Robert B Kargbo2
1North Dakota State University, Fargo, North Dakota 58108-6050, United States.
Abstract:
New-generation KRAS G12C inhibitors demonstrate enhanced activity in both peripheral and central nervous system malignancies. Frontier Medicines' pyridopyrimidines and Novartis's spiro-indazole inhibitor (opnurasib) overcome resistance mechanisms by targeting both GDP- and GTP-bound KRAS states. Their blood-brain barrier permeability and synergy with immune checkpoint inhibitors represent a transformative advance for KRAS-driven cancers, especially metastatic nonsmall cell lung cancer (NSCLC).
Insights
New KRAS G12C inhibitors show promise against brain and lung cancers. These drugs target KRAS in both GDP- and GTP-bound states, overcoming resistance and improving outcomes for metastatic nonsmall cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS mutations are prevalent in various cancers, including nonsmall cell lung cancer (NSCLC).
- Existing KRAS inhibitors face challenges with resistance mechanisms and central nervous system (CNS) penetration.
- Targeting both GDP- and GTP-bound states of KRAS may overcome acquired resistance.
